A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints
- 11 September 2017
- journal article
- research article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 37 (3) , 1060-1067
Abstract
Background: Overactive bladder is a chronic condition affecting lower urinary tract function that has a significant negative impact on QoL.Objective: Evaluation of the BlueWind implantable tibial nerve system performance and safety in refractory OAB.Design, Setting, and Participants Intervention: A 6‐month multi‐center prospective intervention study.Outcome Measurements and Statistical Analysis: Objective assessment was done by voiding diary parameters including voids/day, volume voided/day, urgency assessment, leaking episodes/day, pads used/day, leak severity, and clinical success defined as a ≥50% reduction in the number of leaks/day or number of voids/day or number of episodes with degree of urgency >2 or a return to <8 voids/day on a 3 Day diary. Subjective assessment was based on OAB‐q including HRQL and symptom severity score. Safety was evaluated by adverse event (AE) analysis.Results and Limitations: Thirty‐four of the 36 implanted subjects completed the study. One subject withdrew voluntarily and one developed inflammation necessitating removal of the system. In the remaining subjects, 71% experienced clinical success at 6 months. Leaks/day, leak severity, and pad changes/day decreased significantly over time with 27.6% of urge incontinence subjects that became “dry.” Voids/day, degree of urgency, volume/void, pads changed improved significantly. All quality of life aspects (concern, coping, sleep, and social) improved as well as symptom severity scores measured by the OAB‐q. Adverse events included: implant site pain (13.9%), suspected infection (22.2%), and procedural wound complications (8.3%).Conclusions: The BlueWind implantable tibial nerve stimulator is a safe, minimally invasive system that affords OAB patients significant improvements.Patient Summary: The performance and safety of the BlueWind RENOVA™ implantable tibial nerve neuromodulator for OAB was tested. Our preliminary results demonstrate that the system has a low risk safety profile and may be considered an effective treatment option for OAB management.Keywords
Funding Information
- BlueWind Medical Ltd., Herzliya ISRAEL
This publication has 22 references indexed in Scilit:
- Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Outcomes of a Prospective, Worldwide Clinical StudyJournal of Urology, 2007
- Responder analyses and the assessment of a clinically relevant treatment effectTrials, 2007
- Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC StudyEuropean Urology, 2006
- Determining the Importance of Change in the Overactive Bladder QuestionnaireJournal of Urology, 2006
- Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome: 12-Month Follow-upNeuromodulation: Technology at the Neural Interface, 2006
- Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: Results of a pilot study with a novel minimally invasive implantable mini‐stimulatorNeurourology and Urodynamics, 2005
- Neuromodulation in voiding dysfunction: a historical overview of neurostimulation and its applicationUrologic Clinics of North America, 2005
- THE USE OF ELECTRICAL DEVICES FOR THE TREATMENT OF BLADDER DYSFUNCTION: A REVIEW OF METHODSJournal of Urology, 2004
- Management of Overactive BladderNew England Journal of Medicine, 2004
- Measurement of health statusControlled Clinical Trials, 1989